TABLE 5.
Meta-analysis of associations of cardiometabolic outcomes with rs33972313 and with l-ascorbic acid within 4 cohorts1
| Change in outcome z score per effect allele2 |
||||||
| Phenotype | n | Expected | Observed | P-rs33972313 association with outcome3 | I2, % | P-difference between observed and expected |
| SBP | 10,402 | −0.01 (−0.02, −0.003) | −0.02 (−0.09, 0.06) | 0.63 | 0 | 0.84 |
| DBP | 10,402 | −0.01 (−0.02, 0.004) | −0.02 (−0.09, 0.05) | 0.56 | 0 | 0.75 |
| Cholesterol | 10,362 | −0.0002 (−0.01, 0.01) | −0.03 (−0.10, 0.04) | 0.44 | 0 | 0.45 |
| HDL cholesterol | 10,083 | 0.01 (−0.0005, 0.02) | −0.06 (−0.16, 0.04) | 0.21 | 39.2 | 0.13 |
| LDL cholesterol | 10,019 | 0.001 (−0.01, 0.01) | −0.04 (−0.11, 0.03) | 0.28 | 0 | 0.27 |
| Triglycerides | 9257 | −0.02 (−0.03, −0.002) | 0.09 (−0.05, 0.22) | 0.21 | 64.0 | 0.13 |
| Glucose | 10,321 | −0.01 (−0.02, 0.003) | 0.03 (−0.04, 0.10) | 0.43 | 0 | 0.30 |
| BMI | 10,377 | −0.01 (−0.02, 0.001) | 0.01 (−0.07, 0.09) | 0.88 | 15.0 | 0.72 |
| WHR | 10,355 | −0.02 (−0.04, −0.01) | −0.02 (−0.09, 0.06) | 0.67 | 0 | 0.84 |
| Hypertension4 | 8580 | 0.99 (0.97, 1.01) | 0.97 (0.76, 1.24) | 0.80 | 0 | 0.88 |
All continuous traits are inverse-rank transformed before calculation of z score. All effect sizes (95% CIs) are presented in SD units. I2 is the percentage of total variance in study estimates that is attributable to between-study heterogeneity (29). DBP, diastolic blood pressure; SBP, systolic blood pressure; WHR, waist-hip ratio.
All values are means; 95% CIs in parentheses. Values are for observed and expected effect sizes and meta-analysis P values.
Values are from a random-effects meta-analysis of linear regression coefficients estimated within each study for each phenotype z score (on the inverse rank scale) against rs33972313 genotype.
Estimates for hypertension were calculated on the log(OR) scale and exponentiated to give an expected OR estimate for hypertension risk.